Payment overview · 2025
General Payments
$339.20
18 reported records · 10 companies
Healthcare provider profile · identity verified
Susan Bourgeois Ieyoub, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1255404521
Verified facts
What the public records show
CMS Open Payments records show Susan Bourgeois Ieyoub, MD received $339.20 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.12 | 23.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.66 | 17.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.48 | 16.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $31.69 | 9.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.46 | 9.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 5.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.98 | 5.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.84 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.09 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.58 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.20 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $57.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.48 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.19 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
171 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
179 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1217 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 681 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 627 | 106 |
| Escitalopram Oxalate | Escitalopram Oxalate | 612 | 79 |
| Gabapentin | Gabapentin | 446 | 62 |
| Furosemide | Furosemide | 434 | 56 |
| Sertraline Hcl | Sertraline Hcl | 409 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 378 | 55 |
| Omeprazole | Omeprazole | 335 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 326 | 60 |
| Metformin Hcl | Metformin Hcl | 316 | 56 |
| Lisinopril | Lisinopril | 283 | 62 |
| Potassium Chloride | Potassium Chloride | 281 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 278 | 53 |
| Montelukast Sodium | Montelukast Sodium | 247 | 49 |
| Memantine Hcl | Memantine Hcl | 239 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 207 | 41 |
| Eliquis | Apixaban | 202 | 29 |
| Buspirone Hcl | Buspirone Hcl | 199 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 47 |
| Losartan Potassium | Losartan Potassium | 183 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 20 |
| Jardiance | Empagliflozin | 179 | 20 |
| Mirtazapine | Mirtazapine | 177 | 23 |
| Synthroid | Levothyroxine Sodium | 171 | 40 |
| Trazodone Hcl | Trazodone Hcl | 169 | 34 |
| Lorazepam | Lorazepam | 155 | 39 |
| Donepezil Hcl | Donepezil Hcl | 154 | 29 |
| Clonazepam | Clonazepam | 153 | 26 |
| Famotidine | Famotidine | 153 | 19 |
| Valsartan | Valsartan | 149 | 38 |
| Alendronate Sodium | Alendronate Sodium | 146 | 37 |
| Carvedilol | Carvedilol | 140 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 28 |
| Ozempic | Semaglutide | 136 | 17 |
| Levetiracetam | Levetiracetam | 123 | suppressed |
| Meloxicam | Meloxicam | 119 | 29 |
| Allopurinol | Allopurinol | 118 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 112 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 23 |
| Mounjaro | Tirzepatide | 109 | 19 |
| Tramadol Hcl | Tramadol Hcl | 102 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 98 | 24 |
| Simvastatin | Simvastatin | 96 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 13 |
| Spironolactone | Spironolactone | 91 | 17 |
| Finasteride | Finasteride | 89 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 18 |
| Glimepiride | Glimepiride | 79 | 15 |
| Bupropion Xl | Bupropion Hcl | 77 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 23 |
| Prednisone | Prednisone | 75 | 27 |
| Temazepam | Temazepam | 73 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 27 |
| Alprazolam | Alprazolam | 71 | 15 |
| Torsemide | Torsemide | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 24 |
| Irbesartan | Irbesartan | 64 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 49 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Telmisartan | Telmisartan | 56 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 55 | 13 |
| Oxcarbazepine | Oxcarbazepine | 55 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Estradiol | Estradiol | 53 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Baclofen | Baclofen | 50 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 16 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 18 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Linzess | Linaclotide | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 34 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Risperidone | Risperidone | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 28 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 25 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Clobazam | Clobazam | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.20 · 18 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, IBSRELA, LINZESS, MOUNJARO, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error